{"schema_version":1,"assessment_id":"eoa_inverse_innovation_exp03_opportunity320_20260801","source_experiment_id":"eoa_inverse_innovation_exp03_full320_20260801","cell_id":"deadweight_loss_reduction__medicine_healthcare","archetype_slug":"deadweight_loss_reduction","domain_slug":"medicine_healthcare","title":"Risk-Tiered Auto-Renewal for Stable Maintenance Therapy","opportunity_summary":"For a narrowly defined cohort with prior approval and documented stability, automatically renew authorization unless specified clinical, misuse, eligibility, or other material-change triggers require substantive review. The testable claim is that changing which cases undergo full renewal review will reduce authorization-attributable treatment gaps and administrative burden without unacceptable safety, appropriateness, equity, utilization, or fiscal harm.","adopter_authorizer":"The payer or benefit-plan authority responsible for authorization policy, acting through accountable medical and pharmacy leadership and subject to applicable coverage, appeal, privacy, and nondiscrimination obligations.","scores":{"meaningful_impact":{"score":4,"rationale":"If the hypothesized causal chain holds, the proposal could preserve indicated treatment continuity while reducing repeated clinician, pharmacy, and authorization-team work. The magnitude remains uncertain because the packet provides no prevalence or effect-size evidence."},"stakeholder_pull":{"score":3,"rationale":"Patients, prescribers, pharmacies, and authorization teams have plausible reasons to value fewer avoidable renewal delays and repeated submissions, while the payer may value retained exception review. Actual demand and whether existing renewals are perceived as burdensome enough to change policy are unsupported."},"incremental_advantage":{"score":4,"rationale":"Unlike the named electronic prior-authorization rival, which accelerates the existing review, this mechanism exempts narrowly defined stable cases from full re-review while retaining exception triggers. Whether this produces a material net benefit over faster review remains untested."},"distinctiveness_plausibility":{"score":2,"rationale":"The mechanism is clearly differentiated from the stated electronic-automation rival, but prior-art status is explicitly unsearched and no evidence distinguishes it from existing exemptions, extended approvals, or renewal policies."},"technical_implementability":{"score":3,"rationale":"A bounded payer cohort, stability criteria, change triggers, escalation, monitoring, and rollback form a plausible implementation structure. Feasibility is constrained by unproven data linkage, trigger reliability, attribution logic, workflow integration, and data integrity."},"adoption_authority_feasibility":{"score":4,"rationale":"The packet identifies a payer or benefit-plan authority with medical and pharmacy leadership that can change authorization policy and defines a narrow, reversible pilot. Therapy-specific obligations, internal governance, and applicable coverage or appeal constraints still require confirmation."},"evidence_readiness":{"score":3,"rationale":"The proposal identifies observable renewal, dispensing, workflow, clinical, equity, utilization, and fiscal outcomes plus explicit falsifiers. It does not yet operationalize eligibility, outcomes, comparison design, accepted margins, subgroup analysis, or halt thresholds, and linked records are prerequisite."},"safety_net_benefit":{"score":4,"rationale":"The design retains review for material change, contraindications, suspected misuse, nonresponse, and eligibility changes; preserves clinician escalation and patient protections; and specifies monitoring, pause, and reversion. Its benefit depends on exception triggers detecting the cases they are meant to protect."},"scalability":{"score":3,"rationale":"The policy pattern could in principle be reused across payer cohorts, but stability definitions, protective triggers, outcome margins, data availability, and governance are likely therapy- and plan-specific. No cross-cohort evidence is supplied."}},"score_confidence":"MODERATE","costs":{"first_evidence":{"band_2026_usd":"50K_TO_250K","scope":"A bounded retrospective baseline study for one maintenance-therapy cohort linking authorization, dispensing, and clinical-workflow records; compare unchanged previously approved cases around renewal with a prespecified control period or matched cases not exposed to renewal friction, including targeted record validation.","confidence":"MODERATE","assumptions":["One cooperating payer or benefit plan supplies linkable records.","The analysis uses existing data rather than prospective enrollment.","Clinical and operational experts define attribution and review a limited validation sample.","The estimate includes data engineering, privacy and compliance work, clinical review, analysis, and reporting."]},"initial_deployment_startup":{"band_2026_usd":"250K_TO_1M","scope":"Design and configure one narrow, expiring pilot, including eligibility logic, exception triggers, authorization-system changes, escalation workflows, governance approval, monitoring definitions, training, testing, and rollback capability.","confidence":"LOW","assumptions":["The payer can modify an existing authorization platform rather than replace it.","Only one therapy cohort and a limited set of workflows are included.","No new clinical device or major enterprise data platform is required.","External legal, regulatory, and contractual requirements are not yet known."]},"operational_launch":{"band_2026_usd":"250K_TO_1M","scope":"Launch and evaluate the bounded cohort under concurrent protected-outcome monitoring, including implementation support, reviewer and clinician escalation capacity, data-quality checks, subgroup analysis, and independent or separated evaluation functions.","confidence":"LOW","assumptions":["Enrollment and duration remain limited enough for rapid rollback.","Existing pharmacy and payer transaction channels can support the policy.","Serious events and inappropriate continuation require manual review.","The band excludes expansion to additional therapies, payers, or jurisdictions."]},"annual_recurring":{"band_2026_usd":"250K_TO_1M","scope":"Ongoing operation for one established cohort, including rules maintenance, exception review, escalation, audits, safety and equity surveillance, utilization and fiscal analysis, compliance support, and periodic reauthorization of the policy.","confidence":"LOW","assumptions":["Only one bounded cohort is maintained.","Monitoring remains more intensive than routine claims administration.","Exception volume is manageable within existing clinical leadership structures.","Patient volume, trigger frequency, and displaced workload are unknown."]}},"research_burden":"HIGH","earliest_credible_horizon":"3_TO_12_MONTHS","pipeline_gates":{"recognizable_externally_supportable_problem":{"status":"YES","reason":"The candidate specifies observable renewal-pending days, medication gaps, abandoned fills, repeated document requests, and staff rework in unchanged previously approved cases, and identifies linked records capable of supporting or falsifying the problem."},"identifiable_adopter_or_authorizer":{"status":"YES","reason":"The payer or benefit-plan authority responsible for authorization policy, acting through accountable medical and pharmacy leadership, is explicitly identified."},"distinct_testable_incremental_claim":{"status":"YES","reason":"The proposal changes which stable cases require full re-review rather than merely accelerating review, with comparative claims covering authorization-attributable gaps, burden, safety, appropriateness, equity, utilization, and fiscal outcomes."},"bounded_next_evidence_step":{"status":"YES","reason":"A retrospective linked-record study of one narrowly specified cohort can test whether unchanged cases experience renewal-attributable gaps or work and whether substantive review commonly changes management before any live policy change."},"no_unresolved_safety_or_authority_stop":{"status":"YES","reason":"The candidate identifies the responsible authority and excludes material-change, contraindication, suspected-misuse, and changed-eligibility cases; a record-based first study introduces no auto-renewal exposure. Any later pilot remains conditional on operational triggers, thresholds, governance, and rollback."},"implementation_cost_scope_and_range":{"status":"YES","reason":"The one-cohort scope and required functions—data linkage, rules configuration, escalation, compliance, monitoring, evaluation, and rollback—support broad resource-equivalent ranges, although volume and system complexity make confidence low for deployment costs."}},"blocking_evidence":["Linked-record evidence that renewal itself contributes materially to gaps, abandonment, or avoidable work after accounting for affordability, stock, adherence, and prescribing delays.","The frequency with which substantive renewal review changes clinical management, eligibility, or coverage in otherwise apparently stable cases.","Validated performance of proposed stability criteria and exception triggers, including missed contraindications, deterioration, misuse, nonresponse, and eligibility changes.","Prespecified comparison design, outcome definitions, accepted noninferiority or harm margins, subgroup analyses, escalation standards, and halt thresholds.","Evidence that the design does not create unacceptable inequity, inappropriate continuation, excess utilization, fiscal harm, privacy failure, or displaced workload.","Prior-art and policy evidence establishing the nearest implemented comparators and any genuinely distinguishing feature."],"next_evidence_step":"Conduct a preregistered retrospective linked-record study for one proposed therapy cohort. Compare unchanged, previously approved cases during renewal windows with matched stable cases or within-case nonrenewal periods, and measure authorization-attributable dispensing gaps, abandonment, repeated requests, staff work, and the rate at which substantive review changes management. Falsify advancement if renewal exposure is not associated with materially greater attributable disruption or if full review commonly produces clinically or eligibility-relevant changes that proposed triggers would miss.","research_questions":["How often do unchanged, previously approved cases experience dispensing gaps, abandonment, or repeated work specifically attributable to renewal rather than affordability, stock, adherence, or prescribing delay?","How often does full renewal review identify a clinically important change, inappropriate continuation, misuse concern, coverage error, or eligibility change?","Which observable criteria define stability, and what sensitivity and subgroup performance do exception triggers achieve for cases requiring substantive review?","How does risk-tiered auto-renewal compare with faster electronic prior authorization on total burden and treatment continuity?","What safety, appropriateness, equity, utilization, fiscal, escalation-failure, and data-integrity margins should govern any later pilot?","Do existing authorization exemptions, extended approvals, or renewal policies already implement the mechanism, and what testable feature, if any, distinguishes this proposal?"],"recommendation":"PARTNERED_RESEARCH","uncertainty_constraints":["Problem prevalence and effect size are unsupported hypotheses.","World novelty, prior art, implemented-policy prevalence, and market size are unmeasured.","Eligibility rules, triggers, attribution methods, outcome definitions, margins, and halt thresholds are not operationalized.","Data availability, linkage quality, privacy requirements, transaction-system compatibility, and displaced workload are unknown.","Therapy-specific clinical risk and payer-specific legal, contractual, coverage, appeal, and governance constraints are unresolved.","All cost bands are resource-equivalent planning ranges rather than observed or quoted costs."],"closed_book_prior_art_boundary":"No external search or prior-art evidence was used. The packet labels prior art as unsearched, so novelty and differentiation beyond the stated electronic prior-authorization rival remain unestablished; no claim is made about existing policies, prevalence, market size, realized impact, or exact cost."}